癌症疫苗：市場預測・藥物開發及產品線分析

癌症疫苗：市場預測・藥物開發及產品線分析 是由出版商Kalorama Information在2008年11月所出版的。 這份英文市場調查報告書包含250 pages 價格從美金3995起跳。

簡介

目錄

Abstract

It is the general consensus of scientists that cancer vaccines will become a reality. Overall the cancer treatment market continues to grow and this demand sets the stage for vaccine products.

Several promising vaccines: the propholactic Gardasil has created a pathway for new vaccine products. M-Vax, Ocon-Vax in late stage development and are preparing for regulatory review in the United States, Europe, Canada, or other international regions. Many of the products with potential approval status over the coming years are already in Phase III development, have orphan drug status, SPA status, or Fast Track status. This provides a promising future for many of these products. Additionally, some products in international regions have been granted compassionate use status which is significant in evaluating need on a patient-by-patient basis. In this report, Kalorama Information provides a realistic estimate of the cancer vaccine for the near term for the following products:

• Melonoma Vaccines
• Lung Cancer Vaccines
• Prostate Cancer Vaccines
• Cervical Cancer Vaccines
• Brain Cancer Vaccines
• Colon/Rectal Cancer Vaccines
• Breast Cancer Vaccines
• Lymphoma Vaccines
• Ovarian Cancer Vaccines
• Leukemia Vaccines
• Bladder Cancer Vaccines

As part of its exhaustive research and analysis, this report provides:

• Forecasts for Future Revenues from Cancer Vaccines
• Cancer Epidemiology
• Reviews of Products in the Pipeline
• Detailed Profiles of 13 Companies Operating in the Cancer Vaccine Market
• Directory of Related Companies

Some of the issues discussed in this report important for anyone operating in this market include:

• Introduction
• Early Detection and Screening
• Monoclonal Antibodies and Therapeutic Vaccines
• Political and Social Pressure
• Insurance and Reimbursement Issues
• Personalized Medicine
• Pharmacogenomics
• Vaccine Strategies
• New Genetic Technique
• Future Growth in Vaccines

As part of its detailed coverage of developments in cancer vaccines..the following companies are profiled in this report:

• Antigenics, Inc.
• Avax Technologies, Inc.
• Biovest International, Inc.
• Cell Genesys, Inc.
• Dendreon Corporation
• Genitope Corporation
• GlaxoSmithKline plc
• Merck & Company, Inc.
• Northwest Biotherapeutics, Inc.
• NovaRx
• Oncothyreon
• Vaccinogen
• Vical, Inc.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

• Introduction
• Scope and Methodology
• Size and Growth of the Market
• Issues and Trends Affecting Market
• Leading Competitors

CHAPTER TWO: INTRODUCTION

• Introduction
• History and Growth of the Cancer Treatment Market
• Types of Vaccines
  • Antigen/Adjuvant Vaccines
  • Whole Cell Tumor Vaccines
  • Dendritic Cell (DC) Vaccines
  • Viral Vectors and DNA Vaccines
  • Idiotype Vaccines
• Types of Therapeutic Vaccines
  • Patient-Specific Vaccines
  • Prostate Specific Antigen
  • Sialyl Tn
  • Heat Shock Proteins
  • Ganglioside Molecules
  • Carcinoembryonic Antigen (CEA)
  • MART-1
  • Tyrosinase
  • Adjuvants
• Industry Structure
• Demographics and Statistics
  • Growing and Aging Population
  • Life Expectancy and Cancer

CHAPTER THREE: CERVICAL CANCER VACCINES

• Overview
• Description of Vaccines on the Market
  • Gardasil/Silgard
  • Cervarix
• Description of Vaccines in Development
  • TG 4001/R3484
  • HspE7
  • Lovaxin C
  • VGX-3100
  • CA-9
• Market Summary
• Current and Potential Competitors and Analysis, 2012

CHAPTER FOUR: COLON/RECTAL CANCER VACCINES

• Overview
• Description of Vaccines on the Market
  • OncoVAX
• Description of Vaccines in Development
  • OncoVAX
  • TroVAX
  • Avicine
  • CEA VRP Vaccine
  • Collidem
  • IMA910
  • Lapuleucel-T
  • Oncophage
  • CDX-1307-01
  • Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
  • MKC1106-PP
• Market Summary
• Potential Competitors and Analysis, 2012

CHAPTER FIVE: LUNG CANCER VACCINES

• Overview
• Description of Vaccines in Development
  • Lucanix
  • MAGE-A3 Peptide
  • Stimuvax
  • EGF Cancer Vaccine
  • GV-1001
  • HyperAcute Lung
  • IDM 2101 (EP-2101)
  • Oncophage
  • INGN 225
  • TG 4010
  • LungVAX
  • Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
  • DC Vax
  • L523S
• Market Summary
• Potential Competitors and Analysis, 2012

CHAPTER SIX: LYMPHOMA VACCINES

• Overview
• Description of Vaccines in Development
  • MyVax
  • BiovaxID
  • FavId
  • TG 1042
• Market Summary
• Potential Competitors and Analysis, 2012

CHAPTER SEVEN: MELANOMA VACCINES

• Overview
• Description of Vaccines on the Market
• Description of Vaccines in Development
  • M-VAX
  • GMK
  • Allovectin-7
  • MDX-1379 with Combination Treatment MDX-010
  • Oncophage
  • MAGE-A3 ASCI 3
  • Uvidem
  • AGI-101H Vaccine
  • ALVAC Vaccine
  • HyperAcute Melanoma
• Market Summary
• Potential Competitors and Analysis, 2012

CHAPTER EIGHT: PROSTATE CANCER VACCINES

• Overview
• Description of Vaccines in Development
  • Provenge
  • DCVax-Prostate
  • GVAX
  • ProstAtak
  • TroVAX
  • Telomerase Cancer Vaccine
  • MVA-BN Prostate
  • HyperAcute Prostate
  • MKC1106-PP
• Market Summary
• Potential Competitors and Analysis, 2012

CHAPTER NINE: BREAST CANCER VACCINES

• Overview
• Description of Vaccines in Development
  • INGN 225
  • CEA VRP Vaccine
  • MVA-BN HER2
  • Lapuleucel-T
  • PX 104.1
  • CDX-1307-02
  • Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
  • MKC1106-PP
• Market Summary

CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES

• Overview
• Description of Vaccines in Development
  • GV 1001
  • GI-4000
  • Avicine
  • GVAX
  • HyperAcute Pancreas
  • Oncophage
  • CDX-1307-01
  • CRS-100
  • CRS-207
  • DC Vax
  • MKC1106-PP
• Market Summary

CHAPTER ELEVEN: RENAL CANCER VACCINES

• Overview
• Description of Vaccines on the Market
  • Oncophage
• Description of Vaccines in Development
  • Oncophage
  • Reniale
  • TroVAX
  • IMA901
  • AGS-003
  • MDX-1106
  • MKC1106-PP
• Market Summary
• Potential Competitors and Analysis, 2012

CHAPTER TWELVE: BRAIN CANCER VACCINES

• Overview
  • Glioblastoma
  • Neuroblastoma
• Description of Vaccines in Development
  • DCVax-Brain
  • CDX-110
  • GliAtak
  • Oncophage
• Market Summary

CHAPTER THIRTEEN: BLADDER CANCER VACCINES

• Overview
• Description of Vaccines on the Market
  • BCG Therapy (OncoTICE- Organon Teknika) (Immucyst-Sanofi Pasteur)(Pacis-Shire Pharmaceuticals)
• Description of Vaccines in Development
  • Bexidem
  • CG0070
  • MDX-1307-01
• Market Summary

CHAPTER FOURTEEN: OVARIAN CANCER VACCINES

• Overview
• Description of Vaccines in Development
  • OVax Autologous Cell Vaccine
  • Lapuleucel-T
  • Tumor Associated Antigen Therapeutic Vaccine - CEA DNA Cancer Vaccine
  • MKC1106-PP
• Market Summary

CHAPTER FIFTEEN: LEUKEMIA VACCINES

• Overview
• Description of Vaccines in Development
  • GVAX
  • PR1 Peptide Vaccine
  • AGS-005
• Market Summary

CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET

• Introduction
• Early Detection and Screening
• Monoclonal Antibodies and Therapeutic Vaccines
• Political and Social Pressure
• Insurance and Reimbursement Issues
• Personalized Medicine
• Pharmacogenomics
• Vaccine Strategies
• New Genetic Technique
• Future Growth in Vaccines

CHAPTER SEVENTEEN: THE CANCER VACCINE MARKET: MARKET FORECASTS

• Overview
• Total Market Size and Forecast
• Market and Competitor Analysis

CHAPTER EIGHTEEN: CANCER VACCINE CORPORATE PROFILES

• Introduction
• Antigenics, Inc
• Avax Technologies, Inc
• Biovest International, Inc
• Cell Genesys, Inc
• Dendreon Corporation
• Genitope Corporation
• GlaxoSmithKline plc
• Merck & Company, Inc
• Northwest Biotherapeutics, Inc
• NovaRx
• Oncothyreon
• Vaccinogen
• Vical, Inc

CHAPTER NINETEEN: COMPANY NAMES AND ADDRESSES

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

• Table 1-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012
• Figure 1-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012

CHAPTER TWO: INTRODUCTION

• Table 2-1: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
• Figure 2-1: Estimated and Projected World Cancer Incidence by Selected Types of Cancer, 2007 and 2020
• Table 2-2: Total Cancer Incidence by Sex and Country, 2007 Estimates
• Figure 2-2: Total Cancer Incidence by Sex and Country
• Table 2-3: World Population by Selected Geographical Region, 2007-2050
• Figure 2-4: World Population by Selected Geographical Region, 2007-2050
• Table 2-4: Estimated World Population by Age and Geographical Region, 2007
• Figure 2-4: Estimated World Population by Age and Geographical Region, 2007
• Table 2-5: Percent Population Over 65 by Year and Region
• Figure 2-5: Estimated World Population by Age, 2007 and 2050
• Table 2-6: Life Expectancy at Birth by Selected Countries, 2006
• Table 2-6: United States Average Years of Life Lost Per Person Dying of Cancer, All Races, Both Sexes, 2004
• Table 2-7: United States Estimated Person-Years of Life Lost Due to Cancer, All Races, Both Sexes, 2004

CHAPTER THREE: CERVICAL CANCER VACCINES

• Table 3-1: Estimated World Incidence of Cervical Cancer by Country, 2007
• Figure 3-1: Estimated World Incidence of Cervical Cancer by Country, 2007
• Table 3-2: Cervical Cancer Vaccines Approved and in the Pipeline
• Table 3-3: The Developing Cervical Cancer Vaccine Market, 2008-2012
• Figure 3-2: The Developing Cervical Cancer Vaccine Market, 2008-2012
• Table 3-4: The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 3-3: The Developing Cervical Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 3-4: Anticipated Product Sales by Year for Cervical Cancer Vaccines, 2008-2012

CHAPTER FOUR: COLON/RECTAL CANCER VACCINES

• Table 4-1: Estimated World Incidence of Colon/Rectal Cancer by Country, 2007
• Figure 4-1: Estimated World Incidence of Colon/Rectal Cancer by Country, 2007
• Table 4-2: Colon/Rectal Cancer Vaccines in the Pipeline
• Table 4-3: The Emerging Colon/Rectal Cancer Vaccine Market, 2008-2012
• Figure 4-2: The Emerging Colon/Rectal Cancer Vaccine Market, 2008-2012
• Figure 4-3: Anticipated Product Sales by Year for Emerging Colon/Rectal Cancer Vaccines, 2008-2012

CHAPTER FIVE: LUNG CANCER VACCINES

• Table 5-1: Types of Primary Lung Cancer
• Table 5-2: Estimated World Incidence of Lung Cancer by Country, 2007
• Figure 5-1: Estimated World Incidence of Lung Cancer by Country, 2007
• Table 5-3: Lung Cancer Vaccines in the Pipeline

CHAPTER SIX: LYMPHOMA VACCINES

• Table 6-1: Classification of Non-Hodgkin' s Lymphomas
• Table 6-2: Estimated World Incidence of Lymphoma by Country, 2007
• Figure 6-1: Estimated World Incidence of Lymphoma by Country, 2007
• Table 6-3: Lymphoma Vaccines in the Pipeline
• Table 6-4: The Emerging Lymphoma Vaccine Market, 2008-2012
• Figure 6-2: The Emerging Lymphoma Vaccine Market, 2008-2012
• Table 6-5: The Emerging Lymphoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 6-3: The Emerging Lymphoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 6-4: Anticipated Product Sales by Year for Emerging Lymphoma Vaccines, 2010-2012

CHAPTER SEVEN: MELANOMA VACCINES

• Table 7-1: Malignant Condidtions of the Skin
• Table 7-2: Estimated World Incidence of Melanoma by Country, 2007
• Figure 7-1: Estimated World Incidence of Melanoma by Country, 2007
• Table 7-3: Melanoma Vaccines in the Pipeline
• Table 7-4: The Developing Melanoma Vaccine Market, 2008-2012
• Figure 7-2: The Developing Melanoma Vaccine Market, 2008-2012
• Table 7-5: The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 7-3: The Developing Melanoma Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 7-4:Anticipated Product Sales by Year for Developing Melanoma Vaccines, 2010-2012

CHAPTER EIGHT: PROSTATE CANCER VACCINES

• Table 8-1: Estimated World Incidence of Prostate Cancer by Country, 2007
• Figure 8-1: Estimated World Incidence of Prostate Cancer by Country, 2007
• Table 8-2: Prostate Cancer Vaccines in the Pipeline
• Table 8-3: The Emerging Prostate Cancer Vaccine Market, 2008-2012
• Figure 8-2: The Emerging Prostate Cancer Vaccine Market, 2008-2012
• Table 8-4: The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 8-3: The Emerging Prostate Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 8-4: Anticipated Product Sales by Year for Emerging Prostate Vaccines, 2010-2012

CHAPTER NINE: BREAST CANCER VACCINES

• Table 9-1: Estimated World Incidence of Breast Cancer by Country, 2007
• Figure 9-1: Estimated World Incidence of Breast Cancer by Country, 2007
• Table 9-2: Breast Cancer Vaccines in the Pipeline

CHAPTER TEN: GASTROINTESTINAL CANCER VACCINES

• Table 10-1: Estimated World Incidence of Gastrointestinal Cancer by Country, 2007
• Figure 10-1: Estimated World Incidence of Gastrointestinal Cancer by Country, 2007
• Table 10-2: Gastrointestinal Cancer Vaccines in the Pipeline

CHAPTER ELEVEN: RENAL CANCER VACCINES

• Table 11-1: Estimated World Incidence of Renal Cancer by Country, 2007
• Figure 11-1: Estimated World Incidence of Renal Cancer by Country, 2007
• Table 11-2: Renal Cancer Vaccines in the Pipeline
• Table 11-3: The Developing Renal Cancer Vaccine Market, 2008-2012
• Figure 11-2: The Developing Renal Cancer Vaccine Market, 2008-2012
• Table 11-4: The Developing Renal Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 11-3: The Developing Renal Cancer Vaccine Market, Leading Suppliers Shares by Market Revenues, Projected 2012
• Figure 11-4: Anticipated Product Sales by Year for Renal Cancer Vaccines, 2008-2012

CHAPTER TWELVE: BRAIN CANCER VACCINES

• Table 12-1: Estimated World Incidence of Brain Cancer by Country, 2007
• Figure 12-1: Estimated World Incidence of Brain Cancer by Country, 2007
• Table 12-2: Brain Cancer Vaccines in the Pipeline

CHAPTER THIRTEEN: BLADDER CANCER VACCINES

• Table 13-1: Estimated World Incidence of Bladder Cancer by Country, 2007
• Figure 13-1: Estimated World Incidence of Bladder Cancer by Country, 2007
• Table 13-2: Bladder Cancer Vaccines in the Pipeline

CHAPTER FOURTEEN: OVARIAN CANCER VACCINES

• Table 14-1: Estimated World Incidence of Ovarian Cancer by Country, 2007
• Figure 14-1: Estimated World Incidence of Ovarian Cancer by Country, 2007
• Table 14-2: Ovarian Cancer Vaccines in the Pipeline

CHAPTER FIFETEEN: LEUKEMIA VACCINES

• Table 15-1: TYPES OF LEUKEMIA
• Table 15-2: Estimated World Incidence of Leukemia by Country, 2007
• Figure 15-1: Estimated World Incidence of Leukemia Cancer by Country, 2007
• Table 15-3: Leukemia Vaccines in the Pipeline

CHAPTER SIXTEEN: ISSUES AND TRENDS AFFECTING THE CANCER VACCINE MARKET

• Table 16-1: Cancer Detection Tests

CHAPTER SEVENTEEN: THE CANCER VACCINE MARKET: MARKET FORECASTS

• Table 17-1: Cancer Vaccines: Developing and Emerging Cancer VaccineMarkets, 2008-2012
• Figure 17-1: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets, 2008-2012
• Figure 17-2: Cancer Vaccines: Developing and Emerging Cancer Vaccine Markets by Percent and Vaccine Indication, 2012

CANCER VACCINE CORPORATE PROFILES

COMPANY NAMES AND ADDRESSES

相關商品